ORMP - オラメド・ファ―マシュ―ティカルズ (Oramed Pharmaceuticals Inc.) オラメド・ファ―マシュ―ティカルズ

 ORMPのチャート


 ORMPの企業情報

symbol ORMP
会社名 Oramed Pharmaceuticals Inc (オラメド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product an orally ingestible insulin capsule in phase II clinical trials is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801 Oral insulin capsule; ORMD 0901 Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.   オラメド・ファ―マシュ―ティカルズは、イスラエルの製薬会社。経口投与ソリュ―ションの開発を手掛ける。糖尿病治療用経口インスリンをはじめ、他の薬剤やワクチンの投与ソリュ―ションも開発する。主な製品は、経口インスリンカプセル剤の「ORMD-0801」や経口エクセナチドカプセルの「ORMD-0901」。本社はエルサレム。   
本社所在地 142 W. 57th Street New York NY 10019 USA
代表者氏名 Kevin L. Rakin ケヴィン・L・ラッキン
代表者役職名 Chairman of the Board Independent Director
電話番号 +972 2-566-0001
設立年月日 37347
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 14人
url www.oramed.com
nasdaq_url https://www.nasdaq.com/symbol/ormp
adr_tso
EBITDA EBITDA(百万ドル) -13.22500
終値(lastsale) 4.7
時価総額(marketcap) 81604290.5
時価総額 時価総額(百万ドル) 74.13837
売上高 売上高(百万ドル) 2.45000
企業価値(EV) 企業価値(EV)(百万ドル) 50.76537
当期純利益 当期純利益(百万ドル) -12.49700
決算概要 決算概要 BRIEF: For the nine months ended 31 May 2018 Oramed Pharmaceuticals Inc. revenues remained flat at $1.8M. Net loss increased 26% to $9.8M. Revenues reflect market conditions. Higher net loss reflects RESEARCH AND DEVELOPMENT EXPENSES increase of 19% to $9.2M (expense) GENERAL AND ADMINISTRATIVE EXPENSES increase of 67% to $3.1M (expense) FINANCIAL EXPENSES increase of 11% to $72K (expense).

 ORMPのテクニカル分析


 ORMPのニュース

   The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping  2021/03/24 12:59:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 23) BioLife Solutions, Inc. (NASDAQ: BLFS ) ( announced a M&A transaction and quarterly results) Gain Therapeutics, Inc. (NASDAQ: GANX ) (IPOed Thursday) Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) Organogenesis Holdings Inc. (NASDAQ: ORGO ) Soliton, Inc. (NASDAQ: SOLY ) Radius Health, Inc. (NASDAQ: RDUS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows March 23) Adagene Inc. (NASDAQ: ADAG ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Concert Pharmaceuticals, Inc. (NASDAQ: CNCE ) Connect Biopharma Holdings Limited (NASDAQ: CNTB ) (IPOed Friday) Epizyme, Inc. (EPZM) Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) (IPOed Friday) Frequency Therapeutics, Inc. (NASDAQ: FREQ ) Galapagos NV (NASDAQ: GLPG ) Galecto, Inc. (NASDAQ: GLTO ) Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) Ibere Pharmaceuticals (NYSE: IBER-UN) Instil Bio, Inc. (NASDAQ: TIL ) (IPOed Friday) Odonate Therapeutics, Inc. (NASDAQ: ODT ) Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) Soleno Therapeutics, Inc. (NASDAQ: SLNO ) Voyager Therapeutics, Inc. (NASDAQ: VYGR ) Stocks In Focus LabCorp to Review Structure And Capital Allocation Strategy Laboratory Corporation of America Holdings (NYSE: LH ) said its board is undertaking a review of its structure and capital allocation strategy to ensure the company is best positioned to unlock shareholder value while it continues to support patients and customers around the world.
   26 Stocks Moving in Tuesday's Pre-Market Session  2021/03/23 11:15:23 Benzinga
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC ) rose 86.2% to $5.94 in pre-market trading. The surge follows Morgan Stanley disclosing in a filing with the U.S. Securities and Exchange Commission after the markets closed on Monday that it had increased its stake by about 5.2% in the Australian biotechnology company. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) shares rose 56.3% to $16.22 in pre-market trading after gaining over 13% on Monday. The company, last week, reported the formation of a joint venture with Oravax Medical to develop novel oral COVID-19 vaccines. China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD ) rose 33.3% to $1.48 in pre-market trading. BioLife Solutions Inc (NASDAQ: BLFS ) rose 16.7% to $45.00 in pre-market trading after the company reported better-than-expected Q4results. The company announced it will acquire Stirling Ultracold in an all-stock merger. Liquid Media Group Ltd. (NASDAQ: YVR ) rose 31.1% to $5.67 in pre-market trading after jumping over 30% on Monday. The company, last week, announced a $6 million registered direct offering of common shares.
   Së shpejti do të kemi vaksinën e parë si pilulë kundër koronavirusit  2021/03/22 20:31:37 Bota Sot
Provat klinike të vaksinës orale të coronavirusit mund të fillojnë së shpejti dhe të dhënat paraprake janë premtuese. Është një vaksinë e quajtur Oravax e zhvilluar nga kompania izraelito-amerikane, Oramed Pharmaceuticals dhe kompania…...
   This Indian pharma firm is developing oral COVID-19 vaccine in capsule form  2021/03/22 10:15:00 Business Today
Premas Biotech in collaboration with American firm Oramed Pharmaceuticals Inc had announced on March 19 that they are developing an oral COVID-19 vaccine candidate that has shown efficacy upon administration of a single dose
   Perusahaan Israel Buat Vaksin Oral untuk Covid-19  2021/03/22 06:15:15 Republika.co.id
REPUBLIKA.CO.ID, TEL AVIV — Perusahaan farmasi Israel, Oramed Pharmaceuticals Inc dilaporkan sedang bersiap meluncurkan uji klinis tahap pertama dari vaksin oral untuk mencegah infeksi virus corona jenis baru (COVID-19)….
   Oramed Shares Gain On COVID-19 Vaccine Joint Venture Pact - Stocks News Feed  2021/03/19 13:34:17 Stocks News Feed
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) has entered into definitive agreements to form a joint venture focused on developing oral COVID-19 vaccines. The new company, Oravax Medical Inc, will use Oramed’s proprietary POD oral delivery technology and Premas Biotech Pvt. Ltd.’s novel vaccine technology Oravax’s orally delivered COVID-19 vaccine candidate is a virus-like particle (VLP) triple antigen vaccine that targets… Read More »Oramed Shares Gain On COVID-19 Vaccine Joint Venture Pact
   Oramed Shares Gain On COVID-19 Vaccine Joint Venture Pact  2021/03/19 09:34:00 Benzinga
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) has entered into definitive agreements to form a joint venture focused on developing oral …
   Oramed Reaches 25% Randomization in World's First Phase 3 Oral Insulin Study Conducted Under FDA Approved Protocol  2021/03/16 12:25:00 PR Newswire
NEW YORK, March 16, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized 25% of the 675 patients planned…
   ORAMED PHARMACEUTICALS (ORMP) INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Oramed Pharmaceuticals Inc. For Potential Securities Violations and Breaches of Fiduciary Duty  2021/03/02 13:01:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)--Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims against Oramed Pharmaceuticals Inc. (“Oramed” or the “Company”)(NASDAQCM: ORMP). If you currently own shares of Oramed and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/c
   Oral Biologics Market – Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Inc  2021/03/02 08:01:54 OpenPR
Oral Biologics Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities
   ORAMED PHARMACEUTICALS (ORMP) INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Oramed Pharmaceuticals Inc. For Potential Securities Violations and Breaches of Fiduciary Duty  2021/03/02 13:01:00 Business Wire
WILMINGTON, Del.--(BUSINESS WIRE)--Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violations and breach of fiduciary duty claims against Oramed Pharmaceuticals Inc. (“Oramed” or the “Company”)(NASDAQCM: ORMP). If you currently own shares of Oramed and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/c
   Oral Biologics Market – Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Inc  2021/03/02 08:01:54 OpenPR
Oral Biologics Market Report 2021 added recently by Coherent Market Insights, evaluates the industry in terms of market size, market share, revenue estimation, and geographical outlook. The study also delivers a precise summary that illustrates the competitive milieu, growth opportunities
   The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout  2021/02/18 13:14:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 17) Advaxis, Inc. (NASDAQ: ADXS ) Angion Biomedica Corp (NASDAQ: ANGN ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Avanos Medical Inc (NYSE: AVNS ) Bausch Health Companies Inc (NYSE: BHC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bioatla Inc (NASDAQ: BCAB ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Chimerix Inc (NASDAQ: CMRX ) China Biologic Products Holdings Inc (NASDAQ: CBPO ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Endo International PLC (NASDAQ: ENDP ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Krystal Biotech Inc (NASDAQ: KRYS ) Laboratory Corp. of America Holdings (NYSE: LH ) Lucira Health Inc (NASDAQ: LHDX ) Nektar Therapeutics (NASDAQ: NKTR ) (announced a $150-million investment by SFJ Pharma for the Phase 2/3 registrational clinical study of BEMPEG plus Keytruda in patients with head and neck cancer) Oncolytics Biotech, Inc. (NASDAQ: ONCY ) (reacted to initiation of coverage by H.C.
   The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement  2021/01/27 12:35:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 26) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN ) (reacted to new preclinical data showing its investigational asset ASLAN003 have the lowest potential for hepatotoxicity) BIOLASE Inc (NASDAQ: BIOL ) (reacted to its preliminary fourth-quarter results) BioNano Genomics Inc (NASDAQ: BNGO ) CASI Pharmaceuticals Inc (NASDAQ: CASI ) Cassava Sciences Inc (NASDAQ: SAVA ) Clearpoint Neuro Inc (NASDAQ: CLPT ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive data for its monoclonal antibody cocktail in treating COVID-19) ENDRA Life Sciences Inc (NASDAQ: NDRA ) ESSA Pharma Inc (NASDAQ: EPIX ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Illumina, Inc.
   The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market  2021/01/26 13:07:39 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25) Abbott Laboratories (NYSE: ABT ) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Antares Pharma Inc (NASDAQ: ATRS ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) (announced FDA approval for its oral lupus nephritis drug) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Beigene Ltd (NASDAQ: BGNE ) BioNano Genomics Inc (NASDAQ: BNGO ) (reacted to positive sell-side commentary) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearpoint Neuro Inc (NASDAQ: CLPT ) DarioHealth Corp (NASDAQ: DRIO ) DermTech Inc (NASDAQ: DMTK ) Edap Tms SA (NASDAQ: EDAP ) Eli Lilly And Co (NYSE: LLY ) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab) Ekso Bionics Holdings Inc (NASDAQ: EKSO ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Evogene Ltd (NASDAQ: EVGN ) EXACT Sciences Corporation (NASDAQ: EXAS ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Halozyme Therapeutics, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 オラメド・ファ―マシュ―ティカルズ ORMP Oramed Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)